Open: 40.12 Close: 40.11 Change: -0.01

Today's Summary

Moderna president Stephen Hoge spoke about the FDAs decision not to review its flu vaccine. Hoge said the agency asked for supporting analyses from other studies the company had run. Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine. Moderna, Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates. Announces full enrollment of Phase 2 intismeran autogene trial. Moderna reported fourth-quarter results Friday morning that beat Wall Streets muted expectations. FDA declined to review Modernas flu vaccine application.